NextBillion - An Initiative of the William Davidson Institute at the University of Michigan

Thursday, April 21, 2016

Rajiv Malik is president of Mylan, the $9.5-billion, Nasdaq-listed global generic and speciality pharmaceuticals company. Malik became part of Mylan in 2007 when the latter acquired India-based Matrix Laboratories, where he was CEO. That deal also transformed Mylan, which till then operated only in the US, into one of the world’s largest manufacturers of active pharmaceutical ingredients (APIs). On a recent visit to Bengaluru, Malik spoke to TOI:

We know India has become a key part of your operations. Can you give us some quantitative measures of that?

Out of a global workforce of 35,000 employees, more than 15,000 are based out of this country — 1,800 of them are involved in R&D. We have the corporate team for emerging markets in India that determines which are the new countries we want to expand to, what are the strategies we need to adopt and so on. Today, Mylan’s manufacturing platform includes more than 40 facilities, 25 of which are located in India. Those include all nine of our API facilities, eight of our OSD (oral solid doses) facilities, and eight of our injectable facilities, which manufacture our high quality medicines for markets all over the world, including emerging markets.